Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 26401
IPSCIO Record ID: 1774
Property which the Licensor now owns or controls, or hereafter may own or control and which relate to the Licensed Property.
IPSCIO Record ID: 6729
The Innogene License Agreement requires Innogene to purchase 100% of its supplies of Nimotuzumab for non-clinical and clinical studies and trials and 100% of its commercial supplies of Nimotuzumab from Licensor.
Improved Treatment Method for Cancer
review at Patent Office
review at Patent Office
of Treatment of Hormone-Unresponsive Metastatic Prostate Cancer
IPSCIO Record ID: 26428
The Product(s) are Drugs effective against hematologic malignancies and solid tumors as well as other therapeutic indications, such as (but not exclusively) skin disorders and transplantation immunity. All modes of administration, particularly oral and iv., are included in these terms as are specialized formulations such as those imparting controlled-release characteristics.
IPSCIO Record ID: 26640
Â·Recombinant Human Interferon alpha-2a (rHulFN-a 2a) and alpha-2b (rHulFN-a 2b)
Â·Recombinant Human granulocyte colony stimulating factor (rHuG-CSF);
Â·Recombinant Human granulocyte macrophage colony stimulating factor (rHuGM-CSF);
The Company has acquired license to patented technologies related to the production of therapeutic proteins, alpha and beta interferon, Interleukin 2, EPO (erythropoietin) and human growth factors (rHuG-CSF and rHuGM-CSF).
IPSCIO Record ID: 267745
IPSCIO Record ID: 27625
Alfa-interferon, or interferon, is a protein that increases lymphocyte (white blood cell) activity to help clear HCV from the blood and liver. Interferon fights the formation of scar tissue in the liver and has been shown to prolong an individual's life, thus preventing or delaying the need for liver transplantation.
IPSCIO Record ID: 245923
In the agreement, the parties previously entered into, the Collaboration Agreement which, established a cooperative research and development relationship in order to discover, develop and market novel products whose action is based upon the regulation of Signal Transducers and Activators of Transcription ('STATs') involved in [IL-4, IL-12 and gamma interferon] functions.
In the original agreement, the Licensor grants the Japanese Licensee
– an exclusive license to make, have made, use, offer to sell, sell and import Product in the Licensee Territory under the Licensor Technology; and
– a nonexclusive, worldwide license under Licensors rights in and to the Program Know-How and Program Patents for any purpose outside the Field.
With the amendment, the compound is updated and shall mean a substance which is identified by the Parties during the term of the Research Program as either inhibiting or promoting the activity of STATs activated by IL-4, IL-12, gamma interferon or IL-18, except to the extent such activation occurs through a protein that is also active within the IL-1 pathway.
Product shall mean a Drug Candidate, when used as an active ingredient in a pharmaceutical product for use in the Field, including all indications, formulations, line extension or modes of administration thereof.
Licensor have discovered two human transcription factors, STAT6 and STAT4, that are key proteins involved in immune regulation. When overstimulated, these proteins are instrumental in the development of allergy and asthma in the case of STAT6, and in the development of autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease in the case of STAT4. Experiments in animals have demonstrated that disabling these proteins is safe and blocks inappropriate immune responses. These results demonstrate that STAT6 and STAT4 are excellent drug discovery targets. The goal is to discover drugs capable of selectively blocking STAT6 or STAT4 function.